Introduction: The goals of antimicrobial therapy

International Journal of Infectious Diseases

Volumn 7, Issue SUPPL. 1, 2003, Pages

  Song, Jae Hoon ^a,b  

^a Sungkyunkwan University   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEFIXIME; CEPHALOSPORIN DERIVATIVE; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BACTERIAL INFECTION; CONCENTRATION RESPONSE; CONFERENCE PAPER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; HUMAN; MORTALITY; PENICILLIN RESISTANCE;

EID: 0037347278     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(03)90064-6     Document Type: Conference Paper

References (14)

1. World Health Organization. WHO Report on Infectious Diseases. Removing obstacles to healthy development. WHO, 1999. www.who.int/infectious-diseases-report/index. html
2. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31:347-382.
3. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-1754.
4. Marchant CD, Carlin SA, Johnson CE, Shurin PA. Measuring the comparative efficacy of antibacterial agents for acute otitis media: the 'Pollyanna phenomenon'. J Pediatr 1991; 120:72-77.
5. Garau J. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis 2002; 2:404-415.
6. Dagan R, Leibovitz E, Greenberg D, Yagupsky P, Fliss DM, Leiberman A. Early eradication of pathogens from middle ear fluid during antibiotic treatment is associated with improved clinical outcome. Pediatr Infect Dis J 1998; 17:776-782.
7. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47:129-140.
8. Pechère J-C, Lacey L. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 2000; 45:19-24.
9. Dabernat H, Geslin P, Megraud F, et al. Effects of cefixime or co-amoxiclav treatment on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with otitis media. J Antimicrob Chemother 1998; 41:253-258.
10. World Health Organization. WHO Report on Infectious Diseases. Overcoming antimicrobial resistance. WHO, 2000. www.who.int/infectious-diseases-report/index.html
11. Andes D, Craig WA. Animal model pharmacokinetics and phamacodynamics: a critical review. Int J Antimicrob Agents 2002; 19:261-268.
12. Craig WA. Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis 1996; 25:213-217.
13. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-1081.
14. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42:521-527.